COX-2, cell proliferation and PMA in head-and-neck cancer cells

H. James Cao, Hung Yun Lin, Mary K. Luidens, Travis Keating, Jennifer R. Grandis, Faith B. Davis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Phorbol 12-myristate 13-acetate (PMA) affects a variety of cell processes, including proliferation and differentiation. In most normal cell types, PMA enhances proliferation by a protein kinase C (PKC)-dependent mechanism, while the proliferation of cancer cell lines is inhibited by PMA. PMA has been shown to induce cyclooxygenase-2 (COX-2) production in many cell lines. We examined the effect of PMA on functions of induced COX-2 on proliferation of head-and-neck UMSCC-22B cancer cells. PMA was found to inhibit head-and-neck cancer cell proliferation in a cell viability assay and to induce apoptosis. Abundance of p21 protein and p53 in these cells was increased by PMA treatment. The phorbol ester increased p21 expression in 22B cells through the classical PKC pathway and independently of activation of p53. In addition, PMA increased expression of COX-2 in a time-dependent, PKC-requiring manner. COX-2 siRNA increased abundance of both p53 and p21 in 22B cells and importantly potentiated the anti-proliferative effect of PMA. Confocal microscopy revealed that PMA increased nuclear accumulation of COX-2, but not COX-1, and that COX-2 formed complexes with p53, p21 and the coactivator, p300. Chromatin immunoprecipitation showed that nuclear fraction COX-2 and p53 bound to the promoter region of p21. PMA did not significantly increase PGE2 levels in cultured medium of 22B cells, but did increase by 13-fold the levels of PGE2 in the medium of immortalized normal (293T) cells. In conclusion, our results show that PMA inhibits cell proliferation in head-and-neck cancer cells by a mechanism that is potentiated by COX-2 siRNA. The latter results in an increase of p53 and p21 in PMA-treated cancer cells. In the absence of its siRNA, COX-2 is increased in PMA-exposed cancer cells and becomes a nucleoprotein, where it complexes with p53 and p21. Thus, the antiproliferative activity of PMA in 22B cells is moderated by concurrent induction by PMA of COX-2 accumulation; this moderation may be due to reduction by COX-2 of availability of p21 and p53 in the nucleus.

Original languageEnglish
Pages (from-to)203-218
Number of pages16
JournalImmunology, Endocrine and Metabolic Agents in Medicinal Chemistry
Volume9
Issue number4
Publication statusPublished - Dec 2009
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Head and Neck Neoplasms
Acetates
Cell Proliferation
Protein Kinase C
Small Interfering RNA
phorbol-12-myristate
Dinoprostone
Neoplasms
Cell Line
Nucleoproteins
Chromatin Immunoprecipitation
HEK293 Cells
Phorbol Esters
Genetic Promoter Regions
Confocal Microscopy

Keywords

  • Cyclooxygenases
  • Head and neck cancer cells
  • P21
  • P53
  • Phorbol ester
  • Protein kinase C

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Pharmacology

Cite this

Cao, H. J., Lin, H. Y., Luidens, M. K., Keating, T., Grandis, J. R., & Davis, F. B. (2009). COX-2, cell proliferation and PMA in head-and-neck cancer cells. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 9(4), 203-218.

COX-2, cell proliferation and PMA in head-and-neck cancer cells. / Cao, H. James; Lin, Hung Yun; Luidens, Mary K.; Keating, Travis; Grandis, Jennifer R.; Davis, Faith B.

In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 9, No. 4, 12.2009, p. 203-218.

Research output: Contribution to journalArticle

Cao, HJ, Lin, HY, Luidens, MK, Keating, T, Grandis, JR & Davis, FB 2009, 'COX-2, cell proliferation and PMA in head-and-neck cancer cells', Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 9, no. 4, pp. 203-218.
Cao, H. James ; Lin, Hung Yun ; Luidens, Mary K. ; Keating, Travis ; Grandis, Jennifer R. ; Davis, Faith B. / COX-2, cell proliferation and PMA in head-and-neck cancer cells. In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry. 2009 ; Vol. 9, No. 4. pp. 203-218.
@article{864eda4e7dd84fcb9059f1039bc315d9,
title = "COX-2, cell proliferation and PMA in head-and-neck cancer cells",
abstract = "Phorbol 12-myristate 13-acetate (PMA) affects a variety of cell processes, including proliferation and differentiation. In most normal cell types, PMA enhances proliferation by a protein kinase C (PKC)-dependent mechanism, while the proliferation of cancer cell lines is inhibited by PMA. PMA has been shown to induce cyclooxygenase-2 (COX-2) production in many cell lines. We examined the effect of PMA on functions of induced COX-2 on proliferation of head-and-neck UMSCC-22B cancer cells. PMA was found to inhibit head-and-neck cancer cell proliferation in a cell viability assay and to induce apoptosis. Abundance of p21 protein and p53 in these cells was increased by PMA treatment. The phorbol ester increased p21 expression in 22B cells through the classical PKC pathway and independently of activation of p53. In addition, PMA increased expression of COX-2 in a time-dependent, PKC-requiring manner. COX-2 siRNA increased abundance of both p53 and p21 in 22B cells and importantly potentiated the anti-proliferative effect of PMA. Confocal microscopy revealed that PMA increased nuclear accumulation of COX-2, but not COX-1, and that COX-2 formed complexes with p53, p21 and the coactivator, p300. Chromatin immunoprecipitation showed that nuclear fraction COX-2 and p53 bound to the promoter region of p21. PMA did not significantly increase PGE2 levels in cultured medium of 22B cells, but did increase by 13-fold the levels of PGE2 in the medium of immortalized normal (293T) cells. In conclusion, our results show that PMA inhibits cell proliferation in head-and-neck cancer cells by a mechanism that is potentiated by COX-2 siRNA. The latter results in an increase of p53 and p21 in PMA-treated cancer cells. In the absence of its siRNA, COX-2 is increased in PMA-exposed cancer cells and becomes a nucleoprotein, where it complexes with p53 and p21. Thus, the antiproliferative activity of PMA in 22B cells is moderated by concurrent induction by PMA of COX-2 accumulation; this moderation may be due to reduction by COX-2 of availability of p21 and p53 in the nucleus.",
keywords = "Cyclooxygenases, Head and neck cancer cells, P21, P53, Phorbol ester, Protein kinase C",
author = "Cao, {H. James} and Lin, {Hung Yun} and Luidens, {Mary K.} and Travis Keating and Grandis, {Jennifer R.} and Davis, {Faith B.}",
year = "2009",
month = "12",
language = "English",
volume = "9",
pages = "203--218",
journal = "Anti-Infective Agents in Medicinal Chemistry",
issn = "2211-3525",
publisher = "Bentham Science Publishers",
number = "4",

}

TY - JOUR

T1 - COX-2, cell proliferation and PMA in head-and-neck cancer cells

AU - Cao, H. James

AU - Lin, Hung Yun

AU - Luidens, Mary K.

AU - Keating, Travis

AU - Grandis, Jennifer R.

AU - Davis, Faith B.

PY - 2009/12

Y1 - 2009/12

N2 - Phorbol 12-myristate 13-acetate (PMA) affects a variety of cell processes, including proliferation and differentiation. In most normal cell types, PMA enhances proliferation by a protein kinase C (PKC)-dependent mechanism, while the proliferation of cancer cell lines is inhibited by PMA. PMA has been shown to induce cyclooxygenase-2 (COX-2) production in many cell lines. We examined the effect of PMA on functions of induced COX-2 on proliferation of head-and-neck UMSCC-22B cancer cells. PMA was found to inhibit head-and-neck cancer cell proliferation in a cell viability assay and to induce apoptosis. Abundance of p21 protein and p53 in these cells was increased by PMA treatment. The phorbol ester increased p21 expression in 22B cells through the classical PKC pathway and independently of activation of p53. In addition, PMA increased expression of COX-2 in a time-dependent, PKC-requiring manner. COX-2 siRNA increased abundance of both p53 and p21 in 22B cells and importantly potentiated the anti-proliferative effect of PMA. Confocal microscopy revealed that PMA increased nuclear accumulation of COX-2, but not COX-1, and that COX-2 formed complexes with p53, p21 and the coactivator, p300. Chromatin immunoprecipitation showed that nuclear fraction COX-2 and p53 bound to the promoter region of p21. PMA did not significantly increase PGE2 levels in cultured medium of 22B cells, but did increase by 13-fold the levels of PGE2 in the medium of immortalized normal (293T) cells. In conclusion, our results show that PMA inhibits cell proliferation in head-and-neck cancer cells by a mechanism that is potentiated by COX-2 siRNA. The latter results in an increase of p53 and p21 in PMA-treated cancer cells. In the absence of its siRNA, COX-2 is increased in PMA-exposed cancer cells and becomes a nucleoprotein, where it complexes with p53 and p21. Thus, the antiproliferative activity of PMA in 22B cells is moderated by concurrent induction by PMA of COX-2 accumulation; this moderation may be due to reduction by COX-2 of availability of p21 and p53 in the nucleus.

AB - Phorbol 12-myristate 13-acetate (PMA) affects a variety of cell processes, including proliferation and differentiation. In most normal cell types, PMA enhances proliferation by a protein kinase C (PKC)-dependent mechanism, while the proliferation of cancer cell lines is inhibited by PMA. PMA has been shown to induce cyclooxygenase-2 (COX-2) production in many cell lines. We examined the effect of PMA on functions of induced COX-2 on proliferation of head-and-neck UMSCC-22B cancer cells. PMA was found to inhibit head-and-neck cancer cell proliferation in a cell viability assay and to induce apoptosis. Abundance of p21 protein and p53 in these cells was increased by PMA treatment. The phorbol ester increased p21 expression in 22B cells through the classical PKC pathway and independently of activation of p53. In addition, PMA increased expression of COX-2 in a time-dependent, PKC-requiring manner. COX-2 siRNA increased abundance of both p53 and p21 in 22B cells and importantly potentiated the anti-proliferative effect of PMA. Confocal microscopy revealed that PMA increased nuclear accumulation of COX-2, but not COX-1, and that COX-2 formed complexes with p53, p21 and the coactivator, p300. Chromatin immunoprecipitation showed that nuclear fraction COX-2 and p53 bound to the promoter region of p21. PMA did not significantly increase PGE2 levels in cultured medium of 22B cells, but did increase by 13-fold the levels of PGE2 in the medium of immortalized normal (293T) cells. In conclusion, our results show that PMA inhibits cell proliferation in head-and-neck cancer cells by a mechanism that is potentiated by COX-2 siRNA. The latter results in an increase of p53 and p21 in PMA-treated cancer cells. In the absence of its siRNA, COX-2 is increased in PMA-exposed cancer cells and becomes a nucleoprotein, where it complexes with p53 and p21. Thus, the antiproliferative activity of PMA in 22B cells is moderated by concurrent induction by PMA of COX-2 accumulation; this moderation may be due to reduction by COX-2 of availability of p21 and p53 in the nucleus.

KW - Cyclooxygenases

KW - Head and neck cancer cells

KW - P21

KW - P53

KW - Phorbol ester

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=77249110315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249110315&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77249110315

VL - 9

SP - 203

EP - 218

JO - Anti-Infective Agents in Medicinal Chemistry

JF - Anti-Infective Agents in Medicinal Chemistry

SN - 2211-3525

IS - 4

ER -